Kelcey A Bland1, Amy A Kirkham2, Joshua Bovard3, Tamara Shenkier4, David Zucker5, Donald C McKenzie3, Margot K Davis6, Karen A Gelmon4, Kristin L Campbell7. 1. Rehabilitation Sciences, University of British Columbia, Vancouver, Canada. 2. Department of Biomedical Engineering, University of Alberta, Edmonton, Canada. 3. School of Kinesiology, University of British Columbia, Vancouver, Canada. 4. British Columbia Cancer, Vancouver, Canada. 5. Swedish Cancer Institute, Swedish Medical Center, Seattle, WA. 6. Division of Cardiology, Gordon & Leslie Diamond Health Care Centre, University of British Columbia, Vancouver, Canada. 7. Rehabilitation Sciences, University of British Columbia, Vancouver, Canada; Department of Physical Therapy, University of British Columbia, Vancouver, Canada. Electronic address: kristin.campbell@ubc.ca.
Abstract
BACKGROUND:Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse effect of taxanes. We sought to evaluate the effect of exercise on taxane CIPN in women with breast cancer. PATIENTS AND METHODS: Women (n = 27) were randomized to immediate exercise (IE, during taxane chemotherapy) or delayed exercise (DE, after chemotherapy). Supervised aerobic, resistance, and balance training was offered 3 days a week for 8-12 weeks. CIPN symptoms and quality of life were assessed using the European Organization for Research and Treatment of Cancer Quality of LifeQuestionnaire (EORTC QLQ) C30 and CIPN20 (scored from 0 to 100). The percentage of participants reporting moderate to severe sensory symptoms ('3/4' or '4/4' for CIPN20 sensory items) was also evaluated, along with clinical sensory testing at the lower limb (vibration sense and pinprick). Taxane treatment adherence, including relative dose intensity, was extracted from patient medical records. Assessments occurred at: baseline (before taxane chemotherapy), pre-cycle 4 (before the final taxane cycle), the end of chemotherapy, and follow-up (10-15 weeks after chemotherapy). RESULTS: No differences in the EORTC QLQ CIPN20 symptom scores were detected between groups at any time point. At pre-cycle 4, there was a significant difference between groups in patient-reported moderate to severe numbness in the toes or feet (IE: n = 1, 9%, DE: n = 7, 50%, P = .04) and impaired vibration sense in the feet (IE: n = 2, 18%, DE: n = 10, 83%, P < .01). Overall global health status/quality of life was higher in IE compared to DE at the end of chemotherapy (P = .05), yet both groups had worse CIPN20 sensory (Δ24.3 ± 4.6, P < .01) and motor symptom scores (Δ10.5 ± 1.9, P < .01) relative to baseline. By the end of chemotherapy, no differences between groups were found for moderate to severe numbness in the toes or feet (P = 1.0) or impaired vibration sense in the feet (P = .71). More IE participants received ≥ 85% relative dose intensity (IE: n = 12, 100%, DE: n = 10, 67%, P < .05). CONCLUSION:Exercise may attenuate CIPN over the course of taxane chemotherapy and possibly improve taxane adherence in women with breast cancer. These findings, as well as whether exercise can attenuate CIPN by the end of taxane chemotherapy, should be confirmed in larger trials.
RCT Entities:
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse effect of taxanes. We sought to evaluate the effect of exercise on taxane CIPN in women with breast cancer. PATIENTS AND METHODS: Women (n = 27) were randomized to immediate exercise (IE, during taxane chemotherapy) or delayed exercise (DE, after chemotherapy). Supervised aerobic, resistance, and balance training was offered 3 days a week for 8-12 weeks. CIPN symptoms and quality of life were assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30 and CIPN20 (scored from 0 to 100). The percentage of participants reporting moderate to severe sensory symptoms ('3/4' or '4/4' for CIPN20 sensory items) was also evaluated, along with clinical sensory testing at the lower limb (vibration sense and pinprick). Taxane treatment adherence, including relative dose intensity, was extracted from patient medical records. Assessments occurred at: baseline (before taxane chemotherapy), pre-cycle 4 (before the final taxane cycle), the end of chemotherapy, and follow-up (10-15 weeks after chemotherapy). RESULTS: No differences in the EORTC QLQ CIPN20 symptom scores were detected between groups at any time point. At pre-cycle 4, there was a significant difference between groups in patient-reported moderate to severe numbness in the toes or feet (IE: n = 1, 9%, DE: n = 7, 50%, P = .04) and impaired vibration sense in the feet (IE: n = 2, 18%, DE: n = 10, 83%, P < .01). Overall global health status/quality of life was higher in IE compared to DE at the end of chemotherapy (P = .05), yet both groups had worse CIPN20 sensory (Δ24.3 ± 4.6, P < .01) and motor symptom scores (Δ10.5 ± 1.9, P < .01) relative to baseline. By the end of chemotherapy, no differences between groups were found for moderate to severe numbness in the toes or feet (P = 1.0) or impaired vibration sense in the feet (P = .71). More IE participants received ≥ 85% relative dose intensity (IE: n = 12, 100%, DE: n = 10, 67%, P < .05). CONCLUSION: Exercise may attenuate CIPN over the course of taxane chemotherapy and possibly improve taxane adherence in women with breast cancer. These findings, as well as whether exercise can attenuate CIPN by the end of taxane chemotherapy, should be confirmed in larger trials.
Authors: Mary Anne Lagmay Tanay; Jo Armes; Rona Moss-Morris; Anne Marie Rafferty; Glenn Robert Journal: J Cancer Surviv Date: 2021-03-12 Impact factor: 4.442
Authors: Jessica N Mezzanotte; Michael Grimm; Namrata V Shinde; Timiya Nolan; Lise Worthen-Chaudhari; Nicole O Williams; Maryam B Lustberg Journal: Curr Treat Options Oncol Date: 2022-02-15
Authors: Dong-Woo Kang; Rebekah L Wilson; Paola Gonzalo-Encabo; Mary K Norris; Marybeth Hans; Meghan Tahbaz; Jackie Dawson; Danny Nguyen; Amber J Normann; Alexandra G Yunker; Nathalie Sami; Hajime Uno; Jennifer A Ligibel; Steven D Mittelman; Christina M Dieli-Conwright Journal: Front Oncol Date: 2022-06-20 Impact factor: 5.738
Authors: Paola Gonzalo-Encabo; Rebekah L Wilson; Dong-Woo Kang; Mary K Norris; Hajime Uno; Cami N Christopher; Christina Chow; Nathalie Sami; Frank S Fox; Jennifer A Ligibel; Christina M Dieli-Conwright Journal: Front Oncol Date: 2022-05-10 Impact factor: 5.738
Authors: Jana Müller; Markus Weiler; Andreas Schneeweiss; Georg Martin Haag; Karen Steindorf; Wolfgang Wick; Joachim Wiskemann Journal: Br J Cancer Date: 2021-07-05 Impact factor: 7.640